Table 2 Cytokine production in lung homogenates after 30 and 70 days of challenge
From: Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming
Cytokines | time after challenge | non-infected mice | infected mice | immunized with (below) and infected with H37Rv | |||
|---|---|---|---|---|---|---|---|
BCGsc | BCGin | DNA-HSP65 | BCGin/DNA | ||||
IFN-γ (pg/mL) | 30 days | 692 ± 155 | 1069 ± 170 | 890 ± 87 | 1436 ± 185◆, ● | 1332 ± 138 | 2343 ± 397◆, * |
70 days | 634 ± 110 | 795 ± 98 | 866 ± 87 | 1473 ± 120◆, ● | 906 ± 64 | 1753 ± 190◆, * | |
IL-12 (pg/mL) | 30 days | 606 ± 111 | 1281 ± 146 | 1378 ± 213 | 1990 ± 310◆, ● | 1624 ± 254 | 3476 ± 375◆, * |
70 days | 447 ± 131 | 926 ± 56 | 1090 ± 153 | 1562 ± 180◆, ● | 1192 ± 186 | 2709 ± 322◆, * | |
IL-10 (pg/mL) | 30 days | 42 ± 9 | 104 ± 18 | 430 ± 23◆ | 625 ± 79◆, ● | 558 ± 25◆ | 684 ± 104◆, * |
70 days | 30 ± 9 | 84 ± 4 | 391 ± 58◆ | 407 ± 33◆ | 334 ± 14◆ | 572 ± 46◆, * | |
TNF-α (pg/mL) | 30 days | 178 ± 41 | 328 ± 25 | 505 ± 39◆ | 506 ± 58◆ | 470 ± 45◆ | 662 ± 65◆, * |
70 days | 181 ± 43 | 388 ± 25 | 530 ± 22◆ | 574 ± 44◆ | 523 ± 58◆ | 710 ± 52◆, * | |